Replies to post #88671 on Biotech Values

[genisi]

The two main Tekturna outcomes studies are in HF and type-2 diabetes—i.e. neither is a vanilla hypertension study.

That's right but Tekturna is a first with the class of renin inhibitors, which are the first new class of antihypertensives to be launched in over a decade, therefore, I think docs are likely to wait for more data (including outcomes data).